[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100510514":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":11,"locations":25,"responsibleParty":46,"collaborators":11,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":11,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":11,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"BRIM Biotechnology Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"BRM424 Ophthalmic Solution - Dose1","ACTIVE_COMPARATOR",null,[13],"Drug: BRM424 Ophthalmic Solution - Dose1",{"label":15,"type":10,"description":11,"interventionNames":16},"BRM424 Ophthalmic Solution - Dose2",[17],"Drug: BRM424 Ophthalmic Solution - Dose2",[19,23],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","A topical drop of BRM424 ophthalmic solution.",[9],{"type":20,"name":15,"description":21,"armGroupLabels":24,"otherNames":11},[15],[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Wilmington Eye","RECRUITING","Leland","North Carolina","28451","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-78.04471,34.25628,{"lat":38,"lon":37},[41],{"name":42,"role":43,"phone":44,"phoneExt":11,"email":45},"Crystal Wong","CONTACT","910-763-3601","cwong@wilmingtoneye.co",{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100510514","phase-2-assessment-of-the-initial-efficacy-and-safety-of-brm424-ophthalmic-solutions-in-patients-with-neurotrophic-keratitis-100510514",false,"NCT05927428","Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis","An Open-Label, Multi-Center, Phase 2 Dose Ranging Study of BRM424 Ophthalmic Solution in Patients With Neurotrophic Keratitis (NK)","Inclusion Criteria:\n\n* Be at least 18 years of age;\n* Provide written informed consent;\n* Patients with NK Stage 2 (PED) or Stage 3 (corneal ulcer);\n\nExclusion Criteria:\n\n* Any active ocular infection (bacterial, viral, fungal or protozoal) or active ocular inflammation not related to NK;\n* Anticipated need to use therapeutic contact lenses or contact lens wear for refractive correction during the 28-days Treatment Period in the eye(s) with NK;\n* Be a woman of childbearing potential who is not using an acceptable means of birth control;","ALL","18 Years",{"count":58,"type":59},12,"ESTIMATED","INTERVENTIONAL",[62],"PHASE2","The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.",[65],"Neurotrophic Keratitis","2024-10-24",{"date":68,"type":69},"2024-10-28","ACTUAL",{"date":71,"type":69},"2024-07-31",{"date":73,"type":59},"2025-11-30",{"name":5,"class":6},1]